This report describes a case of trans-catheter mitral valve implantation using the second-generation CardiAQ prosthesis in a patient with severe mitral regurgitation.
Case experience with CardiAQ TMVI warrants caution in adoption; leaves open need for prospective trials on durability and outcomes.
Trans-catheter mitral valve implantation (TMVI) is actually the most attractive technique for treating patients with severe mitral regurgitation, who are denied surgical therapy. Recently, trans-catheter implantation of aortic biological prosthesis in mitral position has been done in compassionate cases, and very few experiences of TMVI in native non-calcified valves have been recently reported in very-high-risk patients, mainly with functional mitral regurgitation.Here, we report our case of TMVI using the second-generation CardiAQ prostheisis (CardiAQ Valve Technologies, Irvine, California, USA), reviewing the current state of the art.
No takes yet. Share an insight, caveat, or question.
Romeo et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: